"We are very much looking forward to working together with Jean-Christophe as we continue to advance our business and work ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Looking ahead, ...

In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $55.00. Michael Ulz has given his ...

Shares of The ODP Corporation (ODP) plunged 11.4% after the company reported third-quarter 2024 earnings of $0.71 per share, missing the Zacks Consensus Estimate of $1.49 per share. Ionis ...